Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4801125 | 0.86 | SMN1; SMN2 (0.39) | DRD2HTR2BHTR1ASMN1; SMN2MAPK1 | |
| SCHEMBL4807675 | 0.82 | MAPK1 (0.40) | DRD2HTR2BHTR1ASMN1; SMN2HCRTR1 | |
| SCHEMBL4805657 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL4802914 | 0.78 | KMT2A (0.38) | CSNK1DLMNAMEN1KMT2A | |
| SCHEMBL3166048 | 0.75 | CSNK1D (0.51) | ALOX5CSNK1DMAPK1LMNAMEN1 | |
| SCHEMBL4804670 | 0.74 | NPC1 (0.46) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL3163123 | 0.74 | NPC1 (0.44) | LMNAKMT2A | |
| SCHEMBL4805240 | 0.73 | HDAC1 (0.42) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL3157325 | 0.72 | RORC (0.41) | DRD2HTR2BHTR1ASMN1; SMN2MAPK1 | |
| SCHEMBL4804499 | 0.71 | CCR5 (0.36) | SMN1; SMN2LMNAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | TPH2, HTR6, TPH1 | DRD2 1287/4885HTR2B 21/4885HTR1A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.